XOMA Royalty Corporation Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2021 USD ($) item	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)
Agreements
Payments of consideration under RPAs, AAAs and CPPAs		$ 8,000	$ 15,000
Long-term royalty and commercial payment receivables under the cost recovery method		59,916		$ 55,936
Acquisition of royalty and commercial payment receivables		4,395
Reduction in long-term royalty receivable balance due to receipt of payment		415
Trade and other receivables, net		5,544		1,839
Income from purchased receivables under cost recovery method		5,525
Viracta \| OJEMDA
Agreements
Income from purchased receivables under cost recovery method		5,525
Viracta \| Royalty Purchase Agreement
Agreements
Number of drug candidates \| item	2
Payments of consideration under RPAs, AAAs and CPPAs	$ 13,500
Maximum amount of potential milestones, potential royalties on sales and other payments receivable	54,000
Amount of maximum consideration retained	5,000
Maximum amount of potential regulatory and commercial milestones receivable	57,000
Long-term royalty and commercial payment receivables under the cost recovery method	$ 13,500
Trade and other receivables, net		1,500		$ 1,300
Income from purchased receivables under cost recovery method		5,500	$ 0
Income from purchased receivables under cost recovery method, Milestones		4,000
Income from purchased receivables under cost recovery method, Royalties		$ 1,500